Duloxetine and Famotidine Interaction
Drug interaction information between Duloxetine and Famotidine.
Duloxetine and Famotidine have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Duloxetine and Famotidine. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Taking these two drugs together does not change how much of the medicine gets into your body.
What To Do
You can take these medications together without any special changes to your routine.
FDA Label Information
However, co- administration of Duloxetine delayed-release capsules with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine delayed-release capsules with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose.
Duloxetine Also Interacts With
- Aspirin moderate
- Fluoxetine minor
- Buspirone minor
- Paroxetine minor
- Lorazepam minor
Famotidine Also Interacts With
- Theophylline major
- Tizanidine moderate
- Ketoconazole minor
- Ledipasvir/Sofosbuvir minor
- Itraconazole minor
Frequently Asked Questions
Can I take Duloxetine and Famotidine together?
This is a minor interaction. You can take these medications together without any special changes to your routine.
How serious is the interaction between Duloxetine and Famotidine?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Duloxetine and Famotidine interact?
Taking these two drugs together does not change how much of the medicine gets into your body.
Understanding the Duloxetine and Famotidine Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Duloxetine belongs to the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class and Famotidine belongs to the H2 Receptor Antagonist class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Taking these two drugs together does not change how much of the medicine gets into your body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Duloxetine has 18 total documented interactions on file in this dataset, and Famotidine has 11. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: You can take these medications together without any special changes to your routine. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Duloxetine or Famotidine based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.